| dc.creator |
Macha, Innocent |
|
| dc.creator |
Cazalbou, Sophie |
|
| dc.creator |
Shimmon, Ronald |
|
| dc.creator |
Ben-Nissan, Besim |
|
| dc.creator |
Milthorpe, Bruce K. |
|
| dc.date |
2016-06-21T06:06:59Z |
|
| dc.date |
2016-06-21T06:06:59Z |
|
| dc.date |
2015-07 |
|
| dc.date.accessioned |
2018-03-27T08:37:43Z |
|
| dc.date.available |
2018-03-27T08:37:43Z |
|
| dc.identifier |
Macha, I.J., Cazalbou, S., Shimmon, R., Ben‐Nissan, B. and Milthorpe, B., 2015. Development and dissolution studies of bisphosphonate (clodronate)‐containing hydroxyapatite–polylactic acid biocomposites for slow drug delivery. Journal of tissue engineering and regenerative medicine. |
|
| dc.identifier |
http://hdl.handle.net/20.500.11810/2631 |
|
| dc.identifier |
10.1002/term.2066 |
|
| dc.identifier.uri |
http://hdl.handle.net/20.500.11810/2631 |
|
| dc.description |
An increase in clinical demand on the controlled release of bisphosphonates (BPs) due to complica-tions associated with systemic administration, has been t he current driving force on the developmentof BP drug-release systems. Bisphosphonates have the ability to bind to divalent metal ions, such asCa2+, in bone mineral and prevent bone resorption by influencing the apoptosis of osteoclasts. Local-ized delive ry using biodegradable materials, such as polylactic acid (PLA) and hydroxyapatite (HAp),which are ideal in this approach, have been used in this study to investigate the dissolution ofclodronate (non-nitrogen-containing bisphosphonate) in a new release system. The effects of coralstructure-derived HAp and the release kinetics of the composite s were evaluated. The release kineticsof clodronate from PLA–BP and PLA–HAp–BP systems seemed to follow the power law modeldescribed by Korsmeyer–Peppas. Drug release was quantified by31P-NMR with detection and quanti-fication limits of 9.2 and 30.7 mM, respectively. The results suggest that these biocomposite systemscould be tuned to release clodronate for both rela tively short and prolonged period of time. In addi-tion to drug delivery, the degradation of HAp supplies both Ca2+and phosphate ions that can help inbone mineralization. |
|
| dc.language |
en |
|
| dc.publisher |
Wiley |
|
| dc.subject |
Drug release |
|
| dc.subject |
Thin film composites |
|
| dc.subject |
Coral |
|
| dc.subject |
Hydroxyapatite |
|
| dc.title |
Development and Dissolution Studies of Bisphosphonate (Clodronate)-Containing Hydroxyapatite–Polylactic acid Biocomposites for Slow Drug Delivery |
|
| dc.type |
Journal Article, Peer Reviewed |
|